ArticleMolecular cancer therapeutics2022

Resistance Profile and Structural Modeling of Next-Generation ROS1 Tyrosine Kinase Inhibitors.

Clare Keddy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.